In the single patient who developed distant metastatic disease while receiving NAT, CHC levels initially decreased to zero after initiation of systemic therapy, though subsequently increased prior to discovery of metastases, while still receiving systemic chemotherapy. The gene discussed is BRD2; the disease is metastatic neoplasm.